Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Shares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with its ...

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after ...

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...

Tamibarotene is Syros’ proprietary oral, selective, retinoic acid receptor alpha (RARα) agonist. In the first 190 enrolled patients, the CR rate by intent-to-treat (ITT) in the tamibarotene ...

Syros Pharmaceuticals (SYRS) announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the ...